Vertex focused on programs in CF, hepatitis C and autoimmune diseases in 2013 Vertex’s key strategies and business priorities include: Focusing investment on key development programs for: Cystic Fibrosis, CF: Vertex’s CF strategy is to provide benefit to as many CF patients as possible. Hepatitis C: Vertex’s strategy in hepatitis C is to develop new all-oral treatment regimens of 12 weeks or less in duration with a goal of providing a high viral cure rate and improved tolerability. In 2013, Autoimmune Diseases: Vertex’s strategy in autoimmune diseases is to maximize the value of VX-509 across multiple autoimmune diseases globally. The company will evaluate collaborative opportunities that provide funding and capabilities to broaden and accelerate global development of VX-509. Autoimmune Diseases: Maximizing revenues and cash flow from the appropriate use of INCIVEK®(telaprevir) and KALYDECO in the U.S. and Canada and from the growth of KALYDECO in Europe and other countries 4. Maintaining financial strength to support future growth and shareholder returns.